亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Benzimidazole Derivatives in Breast Cancer: Target-Specific Therapeutic Breakthroughs

乳腺癌 医学 癌症 苯并咪唑 靶向治疗 疾病 抗药性 联合疗法 药品 肿瘤科 重症监护医学 生物信息学 药理学 内科学 生物 化学 有机化学 微生物学
作者
S. Mounika,K Hemalatha,Rohit Pal,Gurubasavaraja Swamy Purawarga Matada,Pallavi Jain,E Haripriya,Md. Ashadul Sk,Mayavan Viji
出处
期刊:Current Topics in Medicinal Chemistry [Bentham Science Publishers]
卷期号:25
标识
DOI:10.2174/0115680266336395241115092048
摘要

Abstract: Despite ongoing advancements in drug design and developments, breast cancer remains a serious and devastating disease and is ranked as the second most common illness in women. Breast cancer rates have increased significantly during the last 40 years. This necessitates the development of novel treatment techniques. Currently, chemotherapy is the primary mode of treatment for breast cancer; however, its toxicity to normal cells and drug resistance are considered the main obstacles. Researchers are looking for novel anti-breast cancer medication classes to improve cancer therapy efficacy and survival rates. Using non-targeting medicines in a 'one-size-fits-all' strategy can harm healthy cells and may not be effective for all patients. Thus, now, the treatment of breast cancer is exploring targeted-based therapy. The tactics involved in this therapy may improve patient survival rates, but their extended usage can lead to significant side effects and medication resistance. Targeted therapy enables precision medicine by targeting particular oncogenic markers in malignancies. Because of their strong cytotoxicity against several cancer cell types, heterocyclic compounds play an important role in the development of therapeutically effective anticancer drugs. Benzimidazole derivatives have grown in favour of anti-breast cancer medicines in recent years due to their broad biological characteristics and therapeutic applications. This review provides healthcare professionals and researchers with an overview of current breakthroughs (2019-2024) in benzimidazole derivatives as breast cancer-targeted therapy, based on the perspectives of leading experts. We have illuminated the diverse and evolving landscape of hybridized benzimidazole, along with its biological targets and anti-breast cancer activity. Further, we also have compiled the various ongoing clinical trials of benzimidazole scaffolds as anti-breast cancer agents. A detailed illustration of the structure-activity connection with special emphasis is provided. The effort may help to develop potent, selective, and effective drugs to combat breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丹牛完成签到,获得积分10
1秒前
loii应助123采纳,获得10
1秒前
5秒前
loii应助123采纳,获得10
8秒前
molihuakai应助初景采纳,获得10
8秒前
寒凡完成签到 ,获得积分10
9秒前
土豆你个西红柿完成签到 ,获得积分10
19秒前
Cheng完成签到 ,获得积分10
26秒前
30秒前
研友_VZG7GZ应助科研通管家采纳,获得10
31秒前
领导范儿应助干净的鸿煊采纳,获得10
31秒前
番茄鱼完成签到 ,获得积分10
34秒前
wanci应助老实的大地采纳,获得10
39秒前
凶狠的寄风完成签到 ,获得积分10
46秒前
46秒前
vv完成签到,获得积分10
49秒前
51秒前
CipherSage应助Faiholo采纳,获得10
52秒前
浮游呦呦完成签到,获得积分0
53秒前
zLin发布了新的文献求助10
54秒前
54秒前
ziw_sysu完成签到,获得积分10
55秒前
初景发布了新的文献求助10
1分钟前
简单完成签到 ,获得积分10
1分钟前
中中完成签到,获得积分10
1分钟前
1分钟前
1分钟前
组大组强发布了新的文献求助10
1分钟前
1分钟前
阔达的冷珍完成签到 ,获得积分10
1分钟前
tidongzhiwu完成签到,获得积分10
1分钟前
chenhui完成签到,获得积分10
1分钟前
1分钟前
1分钟前
沙莎完成签到 ,获得积分10
1分钟前
小蘑菇应助紧张的大有采纳,获得10
1分钟前
tidongzhiwu发布了新的文献求助10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Graphene Handbook (2019 Edition) 800
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
久松真一著作集〈第5巻〉禅と芸術 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6534527
求助须知:如何正确求助?哪些是违规求助? 8327828
关于积分的说明 17839518
捐赠科研通 5636137
什么是DOI,文献DOI怎么找? 2934380
邀请新用户注册赠送积分活动 1910712
关于科研通互助平台的介绍 1769161